PharmaTelevision - Finn Benned Hansen discusses Novo Nordisk’s focus on finding novel compounds and new delivery methods

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Finn Benned Hansen discusses Novo Nordisk’s focus on finding novel compounds and new delivery methods

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Finn Benned Hansen, Corporate VP Strategy and Sourcing, Novo Nordisk.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Finn Hansen role and partnering structure with Novo Nordisk

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I have Finn Hansen, who is Corporate Vice President and Head of Strategy and Sourcing at Novo Nordisk, welcome to the show.

Finn Hansen:

Thank you.

Fintan Walton:

Finn Hansen, Novo Nordisk is obviously very well known for it's insulin based products, but you are here at BIO-Europe here in Munich, in November 2010 and you are here for a purpose obviously to seek up new partnerships, so before we go into what you are looking for could you tell us little bit about you and your role within Novo Nordisk and how partnering is structured within Novo Nordisk?

Finn Hansen:

Certainly, well I head a sourcing group as you said that focuses on finding new opportunities for diabetes and obesity. We also have another group that looks for other biologicals in the inflammatoryarea in for haemostasis and other biologicals, and so our role is to go out and identify and evaluate such opportunities that we find. At Novo Nordisk once we have done careful evaluation and have decided together with a in a dialog with a partner, but there is an interesting opportunity here then we hand over the task to a further do the deal making and the due diligence to our business development group at Novo Nordisk and once and if an agreement is done then we hint the implementation of the agreement and relation to further development of the relationship to the partner to our corporate alliance management group.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Finn Benned Hansen

Corporate Vice President

Finn Hansen , is a Vice President of Business Development and Patents at Novo Nordisk. He is a Director at Novo Nordisk Biotech Fund. Finn Hansen is a very experienced and highly esteemed cross-cultural expert and consultant. He has helped many companies around the world getting the most out of globalisation by focusing on creating competitive advantage and organisational effectiveness. He has done that by helping companies accelerating the synergies from cultural diversity. He has worked in more than 30 different countries at senior management level in companies like IBM, CSC and Arthur Andersen Business Consulting and as managing partner of his own firm he started in 2001, where the client base counts companies like Fortis, Apple, Airbus, SAS, Nordea Bank, Microsoft, Novo Nordisk. He has typically been conducting or involved in: - Cultural due diligence - Post merger integration - Development of corporate cross-cultural training programs - International change management projects - Conflict reconciliation - Strategic direction Finn Hansen holds an MBA from Henley Management College, UK and a doctorate at International School of Management in Paris, New York, Shanghai and Tokyo. The subject of his doctoral thesis is on how cultural diversity is a key success factors for global operating companies. He speaks English, French and Danish fluently and he has worked in more than 30 countries around the globe. He holds an assistant professorship at The International University in Paris.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Novo Nordisk

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,000 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).